Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments
Section snippets
Imiquimod
Imiquimod 5% cream is a topical immunodulating agent that stimulates the body's natural immune system by up-regulating the synthesis of various cytokines such as interferon alfa, tumor necrosis factor (TNF), and interleukin (IL) 12. It has also been shown to indirectly stimulate production of interferon Ī³ and stimulates Langerhans cell migration to locally draining lymph nodes.1, 2, 3, 4 It has just recently been approved by the Food and Drug Administration for the treatment of actinic
Imiquimod
Imiquimod has been shown to be effective in the treatment of superficial and nodular basal cell carcinomas (BCCs). Bianchi et al treated 13 BCCs (9 superficial and 4 nodular) with daily applications of imiquimod for 10 to 18 weeks.34 Only 2 superficial BCCs failed to respond, whereas the other 11 BCCs all cleared with no recurrence up to 6 months after treatment. Erythema, erosion, ulceration, and vesicles occurred in all patients but was well tolerated.34
A study showed the imiquimod as therapy
Imiquimod
Kossard has recently reported the successful use of imiquimod for the treatment of squamous cell carcinoma (SCC) in situ (Bowen's disease) in a 75-year-old woman.52 The lesion in this patient was 6 Ć 5 cm in diameter on the preauricular area and cheek. Imiquimod was applied every other night for a total of 6 weeks. At 4 weeks, the area had enlarged with erosion and hemorrhage but showed no clinical evidence of Bowen's disease at the end of 6 weeks. Three weeks after the 6-week treatment period,
References (53)
- et al.
Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod: an open label trial
J Am Acad Dermatol
(2002) - et al.
Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factor-alpha
J Invest Dermatol
(2000) Effect of topically applied T4 endonuclear V in liposomes on skin cancer in xeroderma pigmentosum: a randomized study. Xeroderma Pigmentosum Study Group
Lancet
(2001)- et al.
Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience
J Photochem Photobiol
(1990) - et al.
Photodynamic therapy with topical methyl aminolevulinate for actinic keratoses: results of a prospective randomized multicenter trial
J Am Acad Dermatol
(2003) - et al.
Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin
J Am Acad Dermatol
(1997) - et al.
Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
J Am Acad Dermatol
(1999) An update on new topical therapies for actinic keratoses: advances and applications
J Drugs Dermatol
(2003)- et al.
Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum
Br J Dermatol
(2000) - et al.
Imiquimod therapy for molluscum contagiosum
J Cutan Med Surg
(2000)
Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology
Int J Dermatol
Successful treatment of actinic keratoses with imiquimod cream 5%: A report of six cases
Br J Dermatol
Imiquimod in the treatment of actinic keratoses and other intraepithelial neoplasms
Int J Dermatol
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses
Int J Dermatol
Actinic keratoses: new treatment options
Adv Dermatol
Clinical improvement of photoaged skin with 50% glycolic acid. A double-blinded vehicle controlled study
Dermatol Surg
A comparison of the efficacy and safety of Jessner's solution and 35% trichloracetic acid vs. 5% fluorouracil in the treatment of widespread facial actinic keratoses
Arch Dermatol
Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses
J Dermatolog Treat
Treatment of solar keratoses with topically applied cytostatic agents
Br J Dermatol
Topical colchicine therapy for actinic keratoses
Dermatology
Topical and light-based treatments for actinic keratoses
Semin Cutan Med Surg
On the role of protoporphyrin IX photoproducts in photodynamic therapy
J Photochem Photobiol
The role of photodynamic therapy in dermatology
Clin Exp Dermatol
A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses
J Am Acad Dermatol
Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study
Dermatology
Cited by (11)
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments
2016, Actas Dermo-SifiliograficasResistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments
2016, Actas Dermo-SifiliograficasComparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma
2008, Journal of Photochemistry and Photobiology B: BiologyTopical chemotherapy for actinic keratosis and nonmelanoma skin cancer: Current options and future perspectives
2007, Actas Dermo-SifiliograficasPigmented nodule below the eye
2010, American Family PhysicianAssessment of the relationship between human papilloma virus infections and cutaneous squamous cell carcinoma
2020, Middle East Journal of Cancer